title: Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones.
abstract: OBJECTIVE
  We evaluated the efficacy of the alpha1-adrenergic antagonist tamsulosin for conservative expulsive therapy in patients with ureteral colic due to juxtavesical stones.
  
  
  METHODS
  A total of 60 consecutive symptomatic patients with stones located in the juxtavesical tract of the ureter were randomly divided into group 1--30 who received oral floroglucine-trimetossibenzene 3 times daily and group 2--30 who received 0.4 mg tamsulosin daily. The 2 groups received 30 mg deflazacort daily for 10 days plus cotrimoxazole 2 times daily for 8 days and 75 mg diclofenac injected intramuscularly on demand. Ultrasound followup and medical visits were performed weekly for 4 weeks. Stone passage rate and time, analgesic use, hospitalization and endoscopical intervention were evaluated. Statistical analysis was performed using the Student t test.
  
  
  RESULTS
  The stone expulsion rate was 70% for group 1 and 100% for group 2. Mean stone size was 5.8 and 6.7 mm, respectively (p = 0.001). Mean expulsion time was 111.1 hours for group 1 and 65.7 hours for group 2 (p = 0.020). The mean number of diclofenac injections was 2.83 for group 1 and 0.13 for group 2 (p <0.0001). Ten group 1 patients were hospitalized, of whom 9 underwent ureteroscopy, compared with none in group 2 (p <0.0001 and 0.001, respectively).
  
  
  CONCLUSIONS
  Tamsulosin used as a spasmolytic drug during renal colic due to juxtavesical calculi increased the stone expulsion rate and decreased expulsion time, the need for hospitalization and endoscopic procedures, and provided particularly good control of colic pain.
authors.affiliation: Department of Urology, A. O. Umberto I-Torrette, University of Ancona, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Dellabella
authors.forename: Giulio
authors.initials: G
authors.lastname: Milanese
authors.forename: Giovanni
authors.initials: G
authors.lastname: Muzzonigro
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D004008:Diclofenac / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006760:Hospitalization; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D011282:Pregnenediones / Q000008:administration & dosage; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage; D014514:Ureteral Calculi / Q000188:drug therapy* / Q000473:pathology
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D000892:Anti-Infective Agents, Urinary; D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; D013449:Sulfonamides; D004008:Diclofenac; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000077409:Tamsulosin; C021988:deflazacort